The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that has an extracellular bilobed venus flytrap domain (VFTD) predicted to contain five calcium (Ca 21 )-binding sites. To elucidate the structurefunction relationships of the VFTD, we investigated 294 unrelated probands with familial hypocalciuric hypercalcaemia (FHH), neonatal severe primary hyperparathyroidism (NSHPT) or autosomal dominant hypocalcaemic hypercalciuria (ADHH) for CaSR mutations and performed in vitro functional expression studies and three-dimensional modelling of mutations involving the VFTD. A total of 70 different CaSR mutations were identified: 35 in FHH, 10 in NSHPT and 25 in ADHH patients. Furthermore, a CaSR variant (Glu250Lys) was identified in FHH and ADHH probands and demonstrated to represent a functionally neutral *
INTRODUCTION
The human calcium-sensing receptor (CaSR) is a 1078-amino acid G-protein-coupled receptor that belongs to family C, which includes the metabotropic glutamate receptors (mGluR) (1) . The CaSR consists of a 612-amino acid extracellular domain (ECD) that is critical for co-translational processing (2), receptor dimerization (3), binding ligands (4) (5) (6) and transmitting activation signals through the seven transmembrane domains (TMDs), which comprises residues 613 -862, and the intracellular domain (ICD), which comprises residues 863-1078 ( Fig. 1) (7) . The ECD is predicted to have a bilobed venus flytrap domain (VFTD) that contains five calcium (Ca 2+ )-binding sites (CaBS-1 to -5), which is consistent with the reported Hill coefficient of 3 (8, 9) . These CaBSs are located near the protein surface and consist of clusters of negatively charged or neutral amino acids (8, 9) . CaBS-1, which is the principal binding site, is located in the cleft between the lobes of the VFTD (8, 9) . Ligand binding by the CaSR VFTD results in the activation of multiple signalling cascades including G q/11 -protein-dependent stimulation of phospholipase C activity, causing an accumulation of inositol 1,4,5-triphosphate and a rapid increase in cytosolic Ca 2+ concentrations ([Ca 2+ ] i ) (10) . These intracellular events mediate a decrease in parathyroid hormone (PTH) secretion from the parathyroid chief cell and a reduction in renal tubular Ca 2+ reabsorption, as illustrated by CaSR mutations which result in alterations in plasma calcium and urinary calcium excretion. For example, inactivating CaSR mutations result in familial hypocalciuric hypercalcaemia (FHH), neonatal severe primary hyperparathyroidism (NSHPT) and primary hyperparathyroidism (PHPT) (11, 12) , whereas activating CaSR mutations result in autosomal dominant hypocalcaemia with hypercalciuria (ADHH), or a form of Bartter syndrome, designated type V (11) . Moreover, in vitro studies, which have functionally expressed these mutant CaSRs and determined their concentration -response curves and the extracellular Ca 2+ concentrations ([Ca 2+ ] o ) needed to produce a halfmaximal (EC 50 ) response in [Ca 2+ ] i , have demonstrated that the inactivating CaSR mutations associated with FHH, PHPT and NSHPT result in a rightward shift of the concentration-response curve and a significantly higher EC 50 ; whereas the activating CaSR mutations associated with ADHH and Bartter syndrome type V result in a leftward shift of the concentration -response curve and a significantly lower EC 50 when compared with the wild-type CaSR (13, 14) . The identification of these disease-causing CaSR mutations has highlighted the importance of the ECD for CaSR function, as many mutations (i.e. 40%) that result in FHH, NSHPT or ADHH cluster in the first 300 ECD residues (15) . To further define the structure -function relationships of the CaSR ECD, we undertook studies to characterize additional CaSR mutations in patients with FHH, NSHPT and ADHH and assessed the functional consequences of those that would increase the understanding of the residues within the VFTD and their relationship with the five CaBSs.
RESULTS

CaSR abnormalities and variants
DNA sequence analysis of the entire 3234 bp coding region and 10 intron-exon boundaries of the CASR was undertaken in 294 unrelated probands, of whom 228 were hypercalcaemic and 66 were hypocalcaemic. This revealed the occurrence of a CASR sequence abnormality in 86 patients (Table 1) , thereby representing a 29% CaSR variant detection rate in this group of patients with hypercalcaemia and hypocalcaemia. Ten abnormalities (Pro55Leu, Thr138Met, Tyr161Cys, Arg172Gly, Arg220Pro, Arg227Gln, Glu250Lys, Leu461Pro, Gly553Arg and Lys831Thr) occurred in more than one patient thereby giving a total of 71 different CaSR abnormalities (Table 1 , Fig. 1 ). The absence of all these DNA sequence abnormalities in 110 alleles from 55 unrelated normal individuals indicated that these abnormalities were mutations or rare polymorphisms that may occur in ,1% of the population. However, one variant (Glu250Lys) was found to occur in FHH and ADHH patients, raising the possibility that this may be a polymorphic variant. To further investigate this, we examined the data from the National Heart Lung and Blood Institute Exome Sequencing Project (NHLBI-ESP) (16) , which provides the exome sequences from 5400 samples, and this revealed that all these abnormalities, except one, which was the Glu250Lys variant, were absent in these exome sequences; the Lys250 variant was present in 0.3% of alleles, indicating that it is a rare polymorphism (16) . Indeed, in vitro functional expression studies demonstrated that the Glu250Lys variant represented a functionally neutral polymorphism (Fig. 2) . The basis of FHH and ADHH in the probands with this Glu250Lys variant is not apparent, as they did not have any other coding region alterations.
Fifty-nine CaSR abnormalities were found in the 228 hypercalcaemic patients, representing a 26% detection rate, and 49 of these CaSR abnormalities were in FHH patients and 10 were in NSHPT patients. Four of the 10 NSHPT-associated CaSR mutations (40%) were nonsense or frameshift mutations that were predicted to lead to a truncated CaSR (Table 1) . This large proportion of truncating mutations in NSHPT differed significantly (P ¼ 0.01) from that of FHH, of which three (9%) mutations were predicted to lead to a truncated CaSR (Table 1, Fig. 3A ). An analysis of previously reported NSHPT mutations also revealed a large proportion of truncating mutations, with .40% being nonsense or frameshift mutations (Fig. 3A) , and this differed significantly (P , 0.01) from the previously reported FHH mutations, of which 11% were predicted to be truncating (Fig. 3A) . All the 10 mutations found in NSHPT patients occurred in the homozygous (n ¼ 8) or compound heterozygous (n ¼ 2) state. The remaining 27 abnormalities of the CaSR were found in the 66 hypocalcaemic patients, representing a 41% detection rate, thereby confirming ADHH as the aetiology for the hypocalcaemia.
Among the 70 different CaSR mutations, 29 (41%) had not been reported in previous studies, and the remaining 41 (59%) had been reported to occur in other, presumably unrelated patients (17, 18) . Forty-four different CaSR mutations (63%) affected ECD residues (Fig. 1) , whereas 22 (31%) mutations affected TMD residues and 4 (6%) mutations affected ICD residues (Table 1 ). An analysis of the location of FHH, NSHPT and ADHH mutations identified in this study, revealed that the majority (.50%) of mutations associated with these hyper-and hypocalcaemic disorders were located in the ECD (Fig. 3B) , and a similar analysis of the 201 different previously reported CaSR mutations (18) also revealed that .50% of the abnormalities associated with such disorders were located in the ECD (Fig. 3B) . The phenotypic features of FHH, NSHPT and ADHH in patients with Figure 1 . Schematic representation of the location of the 71 CaSR variants. The CaSR comprises an ECD, which is formed by residues 1 -612; seven TMDs formed by residues 613-862 and an ICD formed by residues 863-1078. Every 50th amino acid is indicated. The 612-amino acid ECD is consists of the following: an N-terminal signal peptide (amino acids 1-19); a VFTD (amino acids 20-540); a nine cysteine domain (NCD) (amino acids 542-598) and a peptide linker (PL) (amino acids 599 -612) that connects the ECD to the TMD. The residues involved in forming the five VFTD CaBSs are indicated by asterisks. The number preceding the asterisk indicates the respective CaBS. The 71 CaSR variants reported in this study (Table 1) are shown in black. The amino acid change is detailed above the mutated residue. The bracketed letter following the amino acid change indicates whether this variant was identified in a patient with FHH (F), NSHPT (N), ADHH (A) or in both FHH and ADHH (A/F). The location of the Leu173Pro mutation, which has been previously reported in association with FHH (19) , is shown. Boxes indicate the mutations associated with either a loss or a gain of function at codons 173 and 221. The location of the splice site mutation (Table 1) , which is predicted to lead to either a two amino acid missense peptide followed by a stop at codon 167 or an in-frame deletion of exon 4 is shown as S.S. The location of the previously reported Pro339Thr mutation (12) in relation to CaBS-4 residues is also shown. 
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CaSR mutations were similar to those patients without CaSR mutations (data not shown), thereby indicating that phenotypic features alone are unlikely to be useful predictors for the presence or the absence of a CaSR mutation.
Functional characterization of CaSR variants at codons 173, 221 and 250 detected in FHH and ADHH patients
Our DNA sequence analysis of the CASR revealed that variants that would be consistent with missense mutations at codons 173, 221 and 250 were associated with both FHH and ADHH ( (Fig. 2) revealed this not to significantly differ (P ¼ NS) from that of the wild-type receptor (Lys250 versus wild-type ¼ 2.56 + 0.02 versus 2.49 + 0.06 mM). Thus, the Glu250Lys missense substitution, which involved substitution of the negatively charged Glu residue for a positively charged Lys residue, did not alter CaSR function and therefore likely represents a functionally neutral polymorphism. However, the Leu173Phe and Pro221Leu mutations, which involved substitutions of a non-polar residue for another non-polar residue, led to a gain of CaSR function; while the Leu173Pro, which involved substitution of a non-polar residue for another non-polar residue, and Pro221Gln, which Demonstrated to be a functionally neutral polymorphism (Fig. 2) . g Deletion/frameshift, 13 missense peptide followed by a stop at codon 626. h Homozygous mutation. i Compound heterozygous mutation. j Mutations were detected in the same patient. k Deletion/frameshift, 65 amino acid missense peptide followed by a stop at codon 256. l Deletion/frameshift, 27 amino acid missense peptide followed by a stop at codon 938.
involved substitution of the non-polar Pro for a polar Gln, mutations were associated with a loss of CaSR function. This represents a very unusual situation whereby different mutations of a residue can result in opposing functional effects on CaSR responses, such that it appears that the residues at codons 173 and 221 when mutated act as "toggles" which either activate or inactivate the CaSR.
Three-dimensional modelling of VFTD mutations
The two "toggle" residues at Leu173 and Pro221, which are associated with FHH and ADHH, are located in the VFTD (Fig. 1) . Moreover, another 30 CaSR missense mutations identified by our study (Table 1 ) and 93 mutations identified by previous studies (18), i.e. 49 and 46% of all the CaSR mutations, are also located in the VFTD (Fig. 1) . We therefore performed homology modelling, based on the crystal structure of the related mGluR1, to determine the CaSR VFTD threedimensional structure and the functional relationships between the five VFTD CaBSs and the 34 mutations that included the Leu173Phe, Leu173Pro, Pro221Gln and Pro221Leu mutations (Fig. 4) . This revealed that nine of the mutated residues represented by 12 mutations (Thr151Met, Arg172Gly, Leu173Phe, Leu173Pro, Leu174Arg, Arg185Gln, Tyr218His Arg220Pro, Arg220Trp, Pro221Leu, Pro221Gln and Ser296Asn) were located in the cleft between lobes 1 and 2 that contained CaBS-1 (Fig. 4A) ; two mutations (Ile212Ser and Glu241Lys) were adjacent to predicted site 2 ( Fig. 4B ) and six residues represented by eight mutations (Arg172Gly, Trp208Cys, Trp208Ser, Pro221Leu, Pro221Gln, Arg227Gln, Glu228Lys and Cys236Gly) were located within or near to the a-helix that contained predicted site 3 (Fig. 4C) , with three of these (Arg172Gly, Pro221Leu and Pro221Gln) also being in close proximity to site 1. None of the VFTD mutations in our study were present at either predicted CaBS-4 or -5, whereas a Pro339Thr CaSR mutation, which we have previously reported in association with PHPT in adulthood (12) , was shown by our analysis to be located in a short flexible loop that is linked to an a-helix containing CaBS-4 Ca 2+ -binding residues (Fig. 4D) . Thus, 18 of the 34 CaSR missense mutations (i.e. .50%) characterized by our study were located within 10 Å of one or more CaBSs, with the majority (.50%) of CaBS mutations located at site 1 ( Table 2 ). Mutations affecting residues that (Table 1) , and P173, which occurred in an FHH kindred, resulted in a leftward and a rightward shift of the concentration -response curve, respectively, when compared with that of the wild-type CaSR. Thus, the EC 50 values of the mutant CaSRs F173 and P173 were significantly (P , 0.001) lower and higher, respectively, when compared with that of the wild-type CaSR. These findings indicate that the mutant CaSRs F173 and P173 result in a gain of function and a loss of function of the CaSR, respectively, and this is consistent with their associated phenotypes of ADHH and FHH in man. (B) The mutant CaSRs, L221, which occurred in an ADHH kindred (Table 1) , and Q221, which occurred in an FHH kindred, resulted in a leftward and a rightward shift of the concentration-response curve, respectively, when compared with that of the wild-type CaSR. Thus, the EC 50 values of the mutant CaSRs L221 and Q221 were significantly (P , 0.01) lower and higher, respectively, when compared with that of the wild-type CaSR. These findings indicate that the mutant CaSRs L221 and Q221 result in a gain of function and a loss of function of the CaSR, respectively, and this is consistent with their associated phenotypes of ADHH and FHH in man. (C) The variant CaSR, K250, which occurred in both ADHH and FHH kindreds, did not significantly alter the EC 50 or concentration-response curve when compared with that of the wild-type CaSR. The analysis was performed simultaneous with the use of the loss of function P173 CaSR, and a gain of function F173 CaSR, as controls (A). These findings indicate that K250 is a functionally neutral polymorphism (Poly) and not a pathogenic mutation.
were located within 10 Å , which represents approximately twice the diameter of an amino acid residue (20) , of the CaBSs were selected as these are likely to be situated within sufficient proximity to influence interactions between ligand and CaBS residues. A further analysis of the 93 previously reported missense mutations (18) located within the CaSR VFTD revealed that 42 (27 from FHH patients, 5 from NSHPT patients and 10 from ADHH patients) mutations (i.e. 45%) were predicted to be located at or near one or more of the five VFTD CaBSs (Table 2) with .50% located at CaBS-1; these findings are in agreement with our observations of the 70 CaSR mutations (Tables 1 and 2) . A detailed homology modelling analysis of the locations of residues 173 and 221 at the VFTD cleft revealed that both of these amino acid residues are situated at the entrance to CaBS-1 at the cleft region (Fig. 4F) , and hence mutations of these residues would be predicted to influence the entry and binding of Ca 2+ into the VFTD cleft binding site. This location is consistent with the "toggle" role that these residues were found to have in the functional expression studies (Fig. 2) and in their clinical phenotypic expression in being associated with both FHH and ADHH (Table 1 ). Greater than 90% of mutations associated with FHH and ADHH were missense substitutions. However, NSHPT was associated with a significantly (P , 0.05) larger proportion of nonsense and frameshift mutations when compared with either FHH or ADHH. No significant difference in the frequency of mutation types was observed between this study and all the previously reported mutations (18) . (B) Frequencies of ECD, TMD and ICD CaSR mutations in FHH, NSHPT and ADHH patients observed in this study (n ¼ 70) and in an analysis of 201 previously reported CaSR mutations. The majority (.50%) of mutations associated with FHH, NSHPT and ADHH in this study and among the previously reported CaSR mutations were located in the ECD. Significant differences between this study and the previously reported mutations (18) were not observed. In addition, no significant differences in the location of mutations were observed between FHH, NSHPT and ADHH.
DISCUSSION
We report 70 different CaSR mutations that have been identified in 86 unrelated patients with FHH, NSHPT and ADHH (Table 1, Fig. 1 ). The majority (.50%) of these CaSR mutations are missense substitutions located within the ECD (Figs. 1 and 3 ). These and other previously reported diseasecausing mutations highlight the importance of the CaSR ECD, which has a bilobed VFTD that is predicted to contain five CaBSs (Fig. 4) , consistent with the ability of the CaSR to bind Ca 2+ in a cooperative fashion. Thus, our study of disease-causing mutations emphasizes the key role of the represented by a green sphere; and the side chains of predicted CaBS residues are shown in cyan and labelled in yellow. CaSR residues whose mutations resulted in FHH, NSHPT or ADHH (Table 1) and are located within 10 Å of the CaBS are labelled (white) and shown in red. (A) CaBS-1 is comprised of five residues (Ser147, Ser170, Asp190, Tyr218 and Glu297) that are located at the end of a-helices or within flexible loop regions present in the VFTD cleft. Twelve mutations affecting nine residues (Thr151, Arg172, Leu173, Leu174, Arg185, Tyr218, Arg220, Pro221 and Ser296) are located in the VFTD cleft. (B) CaBS-2 is located in lobe 2 and consists of five residues (Asp215, Leu242, Ser244, Asp248 and Gln253) that are situated in an a-helix and two flexible loop regions. The mutated Ile212 and Glu241 residues are located in b-strands that connect to the flexible loop regions of site 2. (C) CaBS-3 is comprised of five Glu residues (codons 224, 228, 229, 231 and 232) that are all located in an a-helix in lobe 2. The site 3 mutated residues are located either in this a-helix (Arg227 and Glu228), adjacent a-helices (Arg172 and Pro221) or in adjacent flexible loops (Trp208 and Cys236). (D) CaBS-4 consists of three Glu residues (codons 350, 353 and 354) located in an a-helix in lobe 1, and two further residues (Asn386 and Ser388) located in an adjacent flexible loop. The previously reported Pro339Thr mutation (Fig. 1 ) associated with isolated PHPT (12) is located in a flexible loop that connects to the lobe 1 a-helix of site 4. (E) CaBS-5 consists of five residues (Glu378, Glu379, Thr396, Asp398 and Glu399) that are located in flexible loop regions in lobe 1. No mutations in this study were situated at site 5. (F) The location of Leu173 and Pro221 amino acid residues at the entrance to the VFTD cleft binding site. The side chains of Leu173 and Pro221 are shown in purple. Leu173 and Pro221 are both predicted to be located in short a-helices in lobes 1 and 2, respectively, which comprise the entrance to CaBS-1 in the VFTD cleft. A white dashed arrow indicates the predicted direction of entry of Ca 2+ into binding site 1. The side chains of both Leu173 and Pro221 are predicted to extend across the entrance of this binding site and therefore mutations at these sites may alter CaSR function through their effects on the entry and binding of Ca 2+ in the cleft region.
extracellular VFTD in binding Ca
2+
. Moreover, homology modelling of the 34 missense mutations (Table 1, Fig. 1 ) which affect VFTD residues revealed that .50% of these mutations are situated within 10 Å of one or more CaBSs (Fig. 4) . The VFTD CaBSs have been previously demonstrated to exhibit differing affinities for Ca 2+ (9) . In particular, VFTD CaBS-2 to -5, when compared with CaBS-1, which is in the VFTD cleft (Fig. 4) , exhibit a lower affinity for Ca 2+ and are considered to be involved only in binding Ca 2+ in hypercalcaemic states (9) . Given the auxiliary role of the sites outside the VFTD cleft in Ca 2+ binding, mutations at CaBS-2 to -5 would be expected to induce a milder alteration in CaSR function than CaBS-1 mutations. This is illustrated by our homology modelling study of a Pro339Thr mutation (12) , which has been reported to lead to a mild loss of function and was associated with normocalcaemia in the heterozygous state (12) , being situated in the proximity of CaBS-4 (Fig. 4) , and hence consistent with a minor role in Ca 2+ binding for CaBSs that are outside the VFTD cleft.
The important role of the VFTD cleft is further illustrated by our identification and functional characterization of mutations involving codons 173 and 221, which are located at the entrance to the VFTD cleft (Fig. 4F) , and lead to either a loss or a gain of CaSR function. Our analysis of the mutations at Leu173 predicted that the introduction of a mutant phenylalanine residue would enhance CaSR activation by increasing the area of interaction with Ca 2+ at the VFTD cleft. The importance of phenylalanine for Ca 2+ binding by the CaSR has previously been demonstrated by studies of Phe270, which is required to complete the coordination sphere for Ca 2+ at CaBS-1 (21) . The introduction of the mutant Pro173 residue was predicted to disrupt an a-helix at CaBS-1 and thereby result in a loss of CaSR function. This a-helix is adjacent to Ser170, which is directly involved in Ca 2+ coordination, and loss of this secondary structure at CaBS-1 may reduce the proximity of Ser170 to Ca 2+ (Fig. 4F) . The predicted derangement of the architecture of CaBS-1, in the mutant Pro173 receptor, is in keeping with the severe loss of function observed in our in vitro studies of this mutant receptor (Fig. 2) . Our analysis of mutations at Pro221 predicted that the activating Leu221 mutation would enhance the Ca 2+ entry into CaBS-1 due to the substitution of the rigid side chain of the wild-type proline residue at the entrance to the VFTD cleft with the more flexible leucine side chain (Fig. 4F) . In contrast, the side chain of the mutant glutamine residue, associated with the Gln221 mutation, would be predicted to extend across the entrance of CaBS-1, thereby impairing ligand entry and leading to a loss of CaSR function. These findings are similar to those reported for mutations of Glu297, which are also associated with opposing effects on CaSR function (21) , and are located in CaBS-1 and the VFTD cleft. Thus, these observations help to demonstrate the importance of the VFTD cleft in being the principal region for the binding of Ca 2+ and in facilitating the cooperative binding of Ca 2+ to the other four CaBSs (9) . However, it is important to note that more than 45% of the VFTD mutations are not located at these CaBSs, thereby indicating that the VFTD likely has other roles in addition to Ca 2+ binding. These roles for the VFTD include: mediating receptor dimerization and cell surface expression (3, 22) ; the binding of different ligands that include amino acids and polyamines (4, 5) and facilitating the transmission of activation signals from the extracellular milieu to the intracellular environment, a process that likely involves the switching of the receptor's VFTD between active and resting conformational states, as shown by studies of the related mGluR1 (23) . Such effects of the non-CaBS VFTD mutations identified by our study on these VFTD functions remain to be elucidated.
The value of undertaking functional characterization studies is demonstrated by our analysis of the Glu250Lys variant, which is located in CaBS-2 (Fig. 4) . This variant has previously been reported by several studies to be a causative mutation in patients with FHH and PHPT (24) (25) (26) and is also listed in the CaSR database (18) as a recurrent mutation. The finding of this Glu250Lys variant in both FHH and ADHH patients in our study (Table 1) suggested that this variant, which involves an evolutionary conserved Glu250 residue, may not be a mutation but instead a functionally neutral polymorphism. We therefore undertook a functional characterization of the Glu250 and Lys250 CaSRs which demonstrated that they each had an EC 50 that was similar (Fig. 2) , thereby indicating that Glu250Lys was not a CaSR mutation but instead a polymorphism. Thus, our finding emphasizes the value of undertaking functional characterization of CaSR variants, which is not generally performed because of time and cost constraints.
Mutations of the CaSR gene were not identified in .70% of the probands, and the phenotypes of these patients without CaSR mutations were similar to those with CaSR mutations. Therefore, it seems likely that other mutations involving the non-coding regions of the CaSR or mutations involving other mediators of calcium regulation may underlie the hyper-and hypocalcaemic phenotypes of these patients. Indeed, the occurrence of such genetic heterogeneity is supported by the identification of two other FHH loci located on chromosomes 19p and 19q13 (27) (28) (29) .
In conclusion, our study reports 70 CaSR mutations identified in patients with FHH, NSHPT or ADHH and demonstrates the value of functional characterization studies by showing that the Glu250Lys variant, which had been previously considered to be a recurrent mutation, is instead a functionally neutral polymorphism. Furthermore, our results reveal that missense mutations of the CaSR ECD cluster at multiple CaBSs, and particularly, in the vicinity of the cleft region formed by the two lobes of the VFTD. Indeed, mutations of residues 173 and 221, located at the entrance to the VFTD cleft, were demonstrated to have opposing effects on receptor function and likely influence receptor function through their 
MATERIALS AND METHODS
Patients
Two hundred and ninety-four index cases were referred to our centre in Oxford (UK) between 2000 and 2010 for germline CaSR mutational analysis, and these consisted of 228 hypercalcaemic patients, in whom a diagnosis had not been established and were being assessed for FHH or NSHPT and 66 hypocalcaemic patients in whom a diagnosis of hypoparathyroidism had not been established and were being investigated for ADHH.
DNA sequence analysis of the CaSR gene
Venous blood was obtained with informed consent, using guidelines approved by the local ethical committee. Leukocyte DNA was extracted and used with CASR specific primers for polymerase chain reaction (PCR) amplification of the exons and intron -exon boundaries, and the DNA sequences of the PCR products were determined, as described (30) . DNA sequence abnormalities were confirmed by restriction endonuclease analysis or by repeat sequence analysis, as described (30) .
Functional expression of CaSR mutations
HEK293 cells (American Type Culture Collection Catalogue no. CRL1573) were transiently transfected using Lipofectamine Plus (Invitrogen) with either a wild-type CaSR construct prepared in an EGFP-N1 plasmid (pEGFP-N1-CaSR) or a construct harbouring the mutation that was introduced by the use of site-directed mutagenesis (QuikChange, Stratagene, La Jolla, CA, USA) (14) . Cells were visualized by fluorescence microscopy (Zeiss, Axiovert S-100) utilizing an epifluorescence filter and images captured using Openlab software (Improvision Inc., Lexington, MA, USA) (31) . Expression of CaSR -EGFP fusion proteins was also confirmed by western blot analysis of cellular protein extract using an anti-GFP monoclonal antibody. The wild-type and mutant CaSRs were functionally assessed by measuring the alterations in [Ca 2+ ] i in response to changes in [Ca 2+ ] o , as described previously (32) . [Ca 2+ ] o concentration -response curves were generated and the EC 50 for each normalized concentration-response curve was determined, as described (14) .
Computer modelling of CaSR VFTD mutations
The crystal structure of the mGluR1 ECD has been determined (23) and was used to model the CaSR ECD. The CaSR ECD has 29% identity and 48% homology at the amino acid level with mGluR1, and the overall secondary and threedimensional structure of the CaSR ECD has been predicted to share close homology with that of the mGluR1 (3, 21, 23) .
We therefore modelled the position of the CaSR mutations based on the mGluR1 framework. The CLUSTAL W multiple sequence alignment program was used to align the protein sequences of the human CaSR and mGluR1 ECDs (33) . MOD-ELLER 9v4 (34) and Pymol (35) were used for structural modelling based on the glutamate and gadolinium ion complexed crystal structure of mGluR1 (Protein Data Bank accession number 1ISR) (36) . CaSR mutations located within 10 Å , which represents approximately twice the diameter of an amino acid residue (range 4.4-6.7 Å ) (20) , of a CaBS were modelled in this study, as these are likely to be situated within sufficient proximity to influence interactions between ligand and CaBS residues.
Statistical analysis
For the in vitro functional expression studies, the mean EC 50 from a minimum of four separate transfection experiments was used for statistical comparison by using the unpaired Student's t-test. A x 2 test was used to analyse mutation frequencies in FHH, NSHPT and ADHH patients.
Bioinformatics analysis
Sequence changes were compared with data from the NHLBI-ESP, which provides the exome sequences from 5400 samples (16) , to assess whether they represent rare polymorphisms that may occur in ,0.1% of the population.
